Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Journal for immunotherapy of cancer·2026
Same author

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Cell·2026
Same author

Bringing in vivo CAR to the clinic: Promise, pitfalls, and questions to ask.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.

British journal of haematology·2026
Same author

Alpha-gal sensitization and allergic blood transfusion reactions: a scoping review.

Journal of translational medicine·2026
Same author

Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.

Blood advances·2025
Same journal

An IL-15 fusion with albumin-binding domain boosts Immunotherapy therapy in glioblastoma via FGF-2 competition regulating FGFR1/2.

Cancer letters·2026
Same journal

Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance.

Cancer letters·2026
Same journal

Aldo-keto Reductase Family 1 Member C3 Suppresses Glioma Progression via Inhibiting Prostaglandin D2-Dependent RhoA/ROCK Signaling.

Cancer letters·2026
Same journal

Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.

Cancer letters·2026
Same journal

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.

Cancer letters·2026
Same journal

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Stem cells in melanoma development.

Marianna Sabatino1, David F Stroncek, Harvey Klein

  • 1Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10 Room 1C711, Bethesda, MD 20892, United States.

Cancer Letters
|December 20, 2008
PubMed
Summary
This summary is machine-generated.

Melanoma treatment resistance and recurrence stem from genetic instability and a subpopulation of cancer stem cells (CSCs). Understanding CSCs is key to improving melanoma therapy outcomes.

More Related Videos

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells
12:21

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells

Published on: March 3, 2016

Related Experiment Videos

Last Updated: Jun 27, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells
12:21

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells

Published on: March 3, 2016

Area of Science:

  • Oncology
  • Dermatology
  • Cancer Biology

Background:

  • Cutaneous melanoma presents a global health challenge with limited treatment efficacy.
  • Therapeutic responses in melanoma patients are often transient, with frequent recurrence.
  • Tumor genetic heterogeneity and instability contribute to melanoma's resistance and recurrence.

Purpose of the Study:

  • To review recent advances in cancer stem cells (CSCs) research.
  • To explore the role of CSCs in melanoma initiation and progression.
  • To discuss the implications of CSCs for melanoma treatment strategies.

Main Methods:

  • Literature review of recent findings on melanoma cancer stem cells.
  • Analysis of studies investigating the genetic basis of melanoma.
  • Synthesis of information on CSCs' role in tumor development and treatment resistance.

Main Results:

  • Melanoma harbors a subpopulation of cancer stem cells (CSCs).
  • CSCs are implicated as the source of primary tumors, metastases, and recurrence.
  • CSCs contribute significantly to therapeutic resistance in melanoma.

Conclusions:

  • Cancer stem cells (CSCs) are crucial in understanding melanoma's natural history.
  • Targeting CSCs may offer novel therapeutic avenues for melanoma.
  • Further research into CSCs is vital for overcoming treatment resistance and improving patient survival.